1. Search Result
Search Result
Isoforms Recommended: TXA2/TP
Results for "

TP receptor

" in MedChemExpress (MCE) Product Catalog:

43

Inhibitors & Agonists

2

Peptides

3

Natural
Products

4

Recombinant Proteins

3

Isotope-Labeled Compounds

1

Antibodies

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-12963
    Dubermatinib
    5+ Cited Publications

    TP-0903

    TAM Receptor Apoptosis Cancer
    Dubermatinib (TP-0903) is a potent and selective Axl receptor tyrosine kinase inhibitor with an IC50 value of 27 nM.
    Dubermatinib
  • HY-16963
    GW627368
    5+ Cited Publications

    Prostaglandin Receptor Inflammation/Immunology Endocrinology Cancer
    GW627368 (GW627368X) is a novel, potent and selective competitive antagonist of prostanoid EP4 receptor with additional human TP receptor affinity, with pKi values of 7.0 and 6.8 for human prostanoid EP4 and TP receptors respectively .
    GW627368
  • HY-147316

    STAT Cancer
    TP-5801 is an orally active TNK1 (non-receptor tyrosine kinase) inhibitor (IC50=1.40 nM), and shows anti-tumor activity .
    TP-5801
  • HY-147316A

    STAT Cancer
    TP-5801 TFA is an orally active TNK1 (non-receptor tyrosine kinase) inhibitor (IC50=1.40 nM), and shows anti-tumor activity .
    TP-5801 TFA
  • HY-160615

    Prostaglandin Receptor Cardiovascular Disease Inflammation/Immunology
    TP receptor antagonist-1 (compound 7m) is a thromboxane A2 receptor (TP receptor) antagonist, with IC50 values of 9.46 μM for TPa and 8.49 μM for TPb, respectively. TP receptor antagonist-1 can be used for the research of cardiovascular disease .
    TP receptor antagonist-1
  • HY-160664

    Prostaglandin Receptor Cardiovascular Disease
    TP receptor antagonist-2 (example 7n) is a thromboxane A2 receptor (TP receptor) antagonist, with IC50 values of 5.64 and 5.27 μM for TPα and TPβ, respectively. TP receptor antagonist-2 inhibits platelet aggregation .
    TP receptor antagonist-2
  • HY-113350

    TXA2

    Prostaglandin Receptor Endogenous Metabolite Inflammation/Immunology Endocrinology Cancer
    Thromboxane A2 (TXA2) is a prostanoid mediator produced by the metabolism of Arachidonic acid (HY-109590) through the cyclooxygenase pathway. Thromboxane A2 activates the thromboxane-prostanoid (TP) receptors. Thromboxane A2 is a potent vasoconstrictor eicosanoid. Thromboxane A2 (TXA2) leads to potent vasoconstriction by stimulation of smooth muscle cells. Thromboxane A2 acts as s tonic immunoregulator to regulate adaptive immune responses .
    Thromboxane A2
  • HY-119127

    Cholecystokinin Receptor Metabolic Disease
    TP-680 is a cholecystokinin receptor antagonist. TP-680 binds 1510 times more strongly to rat pancreatic CCKA receptors (IC50=1.2 nM) than to rat brain CCKB receptors (IC50=1812.5 nM). TP-680 can be used in the study of gastrointestinal diseases .
    TP-680
  • HY-123123

    Prostaglandin Receptor Endogenous Metabolite Cardiovascular Disease
    RS-61756-007 is a selective thromboxane receptor (TP) agonist with high activity at the TP receptor. RS-61756-007 showed agonism at TP and FP receptors in in vitro studies but had no activity at other receptor subtypes. The effects of RS-61756-007 can be antagonized in a similar manner by the TP antagonist SQ 29,548 .
    RS-61756-007
  • HY-118220

    Thrombin Cardiovascular Disease
    EP 171 is a TP receptor agonist and human platelet activator. EP 171 can induce constriction of guinea pig trachea, and the constriction can be inhibited by the TP receptor antagonist EP 092. EP 171 binds to TP receptors on intact human platelets with an IC50 of 2.9 nM .
    EP 171
  • HY-P0316

    Thrombin NO Synthase Cardiovascular Disease
    TP508 is a 23-amino acid nonproteolytic thrombin peptide that represents a portion of the receptor-binding domain of thrombin molecule. TP508 activates endothelial NO synthase (eNOS) and stimulates production of NO in human endothelial cells. TP508 activates endothelial cells and stem cells to revascularize and regenerate tissues .
    TP508
  • HY-P0316A

    Thrombin NO Synthase Cardiovascular Disease
    TP508 TFA is a 23-amino acid nonproteolytic thrombin peptide that represents a portion of the receptor-binding domain of thrombin molecule. TP508 TFA activates endothelial NO synthase (eNOS) and stimulates production of NO in human endothelial cells. TP508 TFA activates endothelial cells and stem cells to revascularize and regenerate tissues .
    TP508 TFA
  • HY-50175

    MK-0524

    Prostaglandin Receptor Inflammation/Immunology Endocrinology
    Laropiprant is a potent and selective DP receptor antagonist with Ki values of 0.57 nM and 2.95 nM for DP receptor and TP Receptor, respectively .
    Laropiprant
  • HY-50175A

    MK-0524 sodium

    Prostaglandin Receptor Inflammation/Immunology
    Laropiprant sodium is a potent and selective DP receptor antagonist with Ki values of 0.57 nM and 2.95 nM for DP receptor and TP Receptor, respectively .
    Laropiprant sodium
  • HY-118014

    Prostaglandin Receptor Cardiovascular Disease
    CAY10535 is a FP and TP receptor inhibitor and can be used for research of cardiovascular diseases .
    CAY10535
  • HY-108972

    Prostaglandin Receptor Metabolic Disease
    SQ 29548, a high affinity radioligand, is a selective thromboxane-prostanoid (TP) receptor antagonist .
    SQ 29548
  • HY-129851

    Prostaglandin Receptor Cardiovascular Disease
    NTP42 is a thromboxane A2 (TXA2) receptor antagonist with an IC50 of 3.278 nM for antagonizing T prostanoid receptor (TP)- mediated [Ca 2+] mobilization following stimulation of cells with the alternative TP agonist U46619 . NTP42 can be used for the treatment of pulmonary arterial hypertension (PAH) .
    NTP42
  • HY-111271A

    Prostaglandin Receptor Inflammation/Immunology Endocrinology
    L 888607 Racemate is a selective prostaglandin D2 receptor subtype 1 (DP1) antagonist, with Kis of 132 nM and 17 nM for DP1 and thromboxane A2 receptor (TP), respectively.
    L 888607 Racemate
  • HY-116281

    Prostaglandin Receptor Cardiovascular Disease
    ICI D1542 is a selective and potent inhibitor of thromboxane A2 (TXA2) synthase and the thromboxane A2 receptor (TP-receptor). ICI D1542 is effective at preventing thrombus formation by redirection of arachidonic acid metabolism .
    ICI D1542
  • HY-108563

    Prostaglandin Receptor Neurological Disease
    SC 51089 is a selective antagonist of prostaglandin E2 EP1 receptor, with Kis of 1.3, 11.2, 17.5, and 61.1 μM for EP1, TP, EP3, and FP receptors, respectively. SC 51089 exhibits neuroprotective activity .
    SC 51089
  • HY-111304

    Prostaglandin Receptor Thrombopoietin Receptor Inflammation/Immunology
    MF266-1 is a selective E prostanoid receptor 1 (EP1) antagonist with an Ki value of 3.8 nM. MF266-1 also has moderate selectivity for thromboxane A2 receptor (TP). MF266-1 is promising for research of arthritis .
    MF266-1
  • HY-13706

    TM30089 Racemate

    Prostaglandin Receptor Endocrinology Cancer
    CAY10471 Racemate (TM30089 Racemate) is a potent and highly selective prostaglandin D2 receptor CRTH2 antagonist, with a Ki of 0.6 nM for hCRTH2, selective over human thromboxane A2 receptor TP (Ki, >10000 nM) or PGD2 receptor DP (Ki, 1200 nM). CAY10471 Racemate also has effect on mouse and rat orthologs of CRTH2 .
    CAY10471 Racemate
  • HY-15007

    Oxytocin Receptor Endocrinology
    L 366509 is a spiroindenylpiperidine camphorsulfonamide oxytocin (OT) antagonist. Modifications led to a new series of o-tolylpiperazine (TP) camphorsulfonamides, exhibiting high affinity for OT receptors and selectivity over arginine vasopressin receptors. Notably, compound 7 (L-368,899) showed excellent OT receptor affinity, potency in inhibiting OT-stimulated uterine contractions, good aqueous solubility, and oral bioavailability in multiple species. Compound 7 has entered clinical testing as an oral and intravenous tocolytic agent. Molecular modeling suggests the TP camphorsulfonamide structure mimics the D-AA2-Ile3 dipeptide, crucial in potent OT antagonists .
    L 366509
  • HY-103512

    GABA Receptor Neurological Disease
    TP003 is a non-selective benzodiazepine site agonist with EC50s of 20.3, 10.6, 3.24, 5.64 nM for α1β2γ2, α2β3γ2, α3β3γ2, α5β2γ2, respectively. TP003 induces anxiolysis via α2GABAA receptors .
    TP003
  • HY-109163

    INS-1009

    Prostaglandin Receptor Inflammation/Immunology Endocrinology
    Treprostinil palmitil (TP) is the proagent of DP1 and EP2 agonist, Treprostinil (UT-15), whose EC50 values were 0.6 and 6.2 nM, respectively. Treprostinil palmitil is a pure proagent and possesses no inherent binding to G-protein coupled receptors including prostanoid receptors .
    Treprostinil palmitil
  • HY-108563A
    SC 51089 free base
    1 Publications Verification

    Prostaglandin Receptor Neurological Disease
    SC 51089 free base is a selective antagonist of prostaglandin E2 EP1 receptor, with Kis of 1.3, 11.2, 17.5, and 61.1 μM for EP1, TP, EP3, and FP receptors, respectively. SC 51089 free base exhibits neuroprotective activity .
    SC 51089 free base
  • HY-118190

    Prostaglandin Receptor Endocrinology
    AL 8810 methyl ester is a prostaglandin F(2α) analog and a prostaglandin F(2α) receptor agonist. Can competitively antagonize the effects of the FP receptor agonist Fluprostenol (HY-108560). AL 8810 methyl ester has no significant potency against TP, DP, EP(2), EP(4) receptor subtypes in cell lines .
    AL 8810 methyl ester
  • HY-50901
    ONO-AE3-208
    Maximum Cited Publications
    9 Publications Verification

    AE 3-208

    Prostaglandin Receptor Endocrinology Cancer
    ONO-AE3-208 is a selective and orally active EP4 receptor antagonist with a Ki of 1.3 nM. ONO-AE3-208 shows less potently affects EP3, FP, and TP receptors (Ki of 30 nM, 790 nM, and 2400 nM, respectively). ONO-AE3-208 suppresses cell invasion, migration, and metastasis of prostate cancer .
    ONO-AE3-208
  • HY-50901A

    AE 3-208 sodium salt

    Prostaglandin Receptor Endocrinology Cancer
    ONO-AE3-208 (sodium salt) is a selective and orally active EP4 receptor antagonist with a Ki of 1.3 nM. ONO-AE3-208 (sodium salt) shows less potently affects EP3, FP, and TP receptors (Ki of 30 nM, 790 nM, and 2400 nM, respectively). ONO-AE3-208 (sodium salt) suppresses cell invasion, migration, and metastasis of prostate cancer .
    ONO-AE3-208 sodium salt
  • HY-50848

    Prostaglandin Receptor Cardiovascular Disease
    BW A868C, a hydantoin compound, is a BW245C structural analogue. BW A868C is a selective and potent competitive prostaglandin D2 (PGD2) antagonist. BW A868C has no effect on other prostaglandin receptors (IP, EP1, EP2, TP and FP) .
    BW A868C
  • HY-116431

    Prostaglandin Receptor Cardiovascular Disease Neurological Disease
    I-BOP is an agonist for thromboxane A2 receptor (TP) with a KD of 0.61 nM. I-BOP promotes proliferation through activation of PI3K pathway in vascular smooth muscle . I-BOP dose-dependently biphasicly affects the excitatory postsynaptic potential (e.p.s.p.) in hippocampal neurons .
    I-BOP
  • HY-130304

    iPE2-III

    Prostaglandin Receptor Cardiovascular Disease
    8-Isoprostaglandin E2 (iPE2-III) is a member of the isoprostane class of prostanoids. 8-Isoprostaglandin E2 acts at the receptor for thromboxane A2 (the TP) in vivo to induce vasoconstriction and platelet aggregation. 8-Isoprostaglandin E2 enhances receptor-activated NFkappa B ligand (RANKL)-dependent osteoclastic potential of marrow hematopoietic precursors via the cAMP pathway .
    8-Isoprostaglandin E2
  • HY-113209

    Endogenous Metabolite Others
    8-Isoprostaglandin F2α is an isoprostane produced by the non-enzymatic peroxidation of arachidonic acid in membrane phospholipids. 8-Isoprostaglandin F2α is present in human plasma in two distinct forms - esterified in phospholipids and as the free acid. 8-Isoprostaglandin F2α is a weak TP receptor agonist in vascular smooth muscle.
    8-Isoprostaglandin F2α
  • HY-B0774
    Seratrodast
    4 Publications Verification

    AA 2414

    Ferroptosis JNK MDM-2/p53 Prostaglandin Receptor Reactive Oxygen Species Neurological Disease Inflammation/Immunology Endocrinology Cancer
    Seratrodast (AA 2414), an orally active antiasthmatic agent, is a thromboxane A2 receptor (TP) antagonist and ferroptosis inhibitor. Seratrodast reduces lipid ROS production, modulates the systemic xc-/GSH/GPX4 axis, and inhibits JNK phosphorylation and p53 expression. Seratrodast exhibits anti-asthmatic and anti-epileptic activity .
    Seratrodast
  • HY-108566
    U-46619
    5+ Cited Publications

    9,11-Methanoepoxy PGH2

    Prostaglandin Receptor Cardiovascular Disease
    U-46619 (9,11-Methanoepoxy PGH2) is a stable analogue of Thromboxane A2 (HY-113350) (TXA2) and acts as a potent TXA2 (TP) agonist. U-46619 also is a RhoA agonist. U-46619 stimulates the activation of RhoA through TXA2 receptor activation .
    U-46619
  • HY-116008

    8-epi PGF3α; 8-iso PGF3α

    Prostaglandin Receptor Endocrinology
    8-iso PGF3α is an isoprostane produced from the free-radical peroxidation of EPA. Little is known about the biological activity of 8-iso PGF3α. There is one report that it is inactive in a TP receptor mediated assay of human platelet shape change, where 8-iso PGF2α has an ED50 value of 1 μM.
    8-iso Prostaglandin F3α
  • HY-123328

    Prostaglandin Receptor Cardiovascular Disease
    AGN 191976 is a potent and selective thromboxane A2-sensitive (TP) receptor agonist with EC50 values ​​of 0.23 nM and 24 nM in rat aorta and human platelets, respectively. AGN 191976 has potent IOP-lowering effects in dogs and monkeys. AGN 191976 can be used to study vascular biology and the role of thromboxane A2 in vascular function .
    AGN 191976
  • HY-125626

    8-iso-15-keto PGF2α

    Prostaglandin Receptor Cardiovascular Disease
    8-iso-15-keto Prostaglandin F2α (8-iso-15-keto PGF2α) is a partial agonist for Thromboxane receptor (TP), which exhibits a vasoconstrictor efficacy with a pD2 of 5.8. 8-iso-15-keto Prostaglandin F2α mediates a weak relaxation of rats aorta rings at high concentration .
    8-iso-15-keto Prostaglandin F2α
  • HY-B0774R

    Ferroptosis JNK MDM-2/p53 Prostaglandin Receptor Reactive Oxygen Species Neurological Disease Inflammation/Immunology Endocrinology Cancer
    Seratrodast (Standard) is the analytical standard of Seratrodast. This product is intended for research and analytical applications. Seratrodast (AA 2414), an orally active antiasthmatic agent, is a thromboxane A2 receptor (TP) antagonist and ferroptosis inhibitor. Seratrodast reduces lipid ROS production, modulates the systemic xc-/GSH/GPX4 axis, and inhibits JNK phosphorylation and p53 expression. Seratrodast exhibits anti-asthmatic and anti-epileptic activity .
    Seratrodast (Standard)
  • HY-130304S

    iPE2-III-d4

    Isotope-Labeled Compounds Prostaglandin Receptor Cardiovascular Disease
    8-Isoprostaglandin E2-d4 (iPE2-III-d4) is deuterium labeled 8-Isoprostaglandin E2. 8-Isoprostaglandin E2 (iPE2-III) is a member of the isoprostane class of prostanoids. 8-Isoprostaglandin E2 acts at the receptor for thromboxane A2 (the TP) in vivo to induce vasoconstriction and platelet aggregation. 8-Isoprostaglandin E2 enhances receptor-activated NFkappa B ligand (RANKL)-dependent osteoclastic potential of marrow hematopoietic precursors via the cAMP pathway .
    8-Isoprostaglandin E2-d4
  • HY-113209S1

    Endogenous Metabolite Others
    8-iso Prostaglandin F2α-d9 is the deuterium labeled 8-Isoprostaglandin F2α. 8-Isoprostaglandin F2α is an isoprostane produced by the non-enzymatic peroxidation of arachidonic acid in membrane phospholipids. 8-Isoprostaglandin F2α is present in human plasma in two distinct forms - esterified in phospholipids and as the free acid. 8-Isoprostaglandin F2α is a weak TP receptor agonist in vascular smooth muscle.
    8-iso Prostaglandin F2α-d9
  • HY-113209S2

    Endogenous Metabolite Isotope-Labeled Compounds Others
    8-Isoprostaglandin F2α- 13C5 is 13C labeled 8-Isoprostaglandin F2α (HY-113209). 8-Isoprostaglandin F2α is an isoprostane produced by the non-enzymatic peroxidation of arachidonic acid in membrane phospholipids. 8-Isoprostaglandin F2α is present in human plasma in two distinct forms - esterified in phospholipids and as the free acid. 8-Isoprostaglandin F2α is a weak TP receptor agonist in vascular smooth muscle.
    8-Isoprostaglandin F2α-13C5
  • HY-113209R

    Endogenous Metabolite Others
    8-Isoprostaglandin F2α (Standard) is the analytical standard of 8-Isoprostaglandin F2α. This product is intended for research and analytical applications. 8-Isoprostaglandin F2α is an isoprostane produced by the non-enzymatic peroxidation of arachidonic acid in membrane phospholipids. 8-Isoprostaglandin F2α is present in human plasma in two distinct forms - esterified in phospholipids and as the free acid. 8-Isoprostaglandin F2α is a weak TP receptor agonist in vascular smooth muscle.
    8-Isoprostaglandin F2α (Standard)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: